Covid's Impact on Outsourced Small Molecule Manufacturing

In Q42020, ISR surveyed 249 sponsors who outsource small molecule manufacturing to learn if their company experienced outsourced manufacturing complications as a result of the Covid-19 pandemic. Small molecule drug substance outsourcers were slightly more likely to report complications than small molecule drug substance outsourcers, 45% vs 40%.